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ABSTRACT
Autoinﬂammatory diseases are characterised by fever
and systemic inﬂammation, with potentially serious
complications. Owing to the rarity of these diseases,
evidence-based guidelines are lacking. In 2012, the
European project Single Hub and Access point for
paediatric Rheumatology in Europe (SHARE) was
launched to optimise and disseminate regimens for the
management of children and young adults with
rheumatic diseases, facilitating the clinical practice of
paediatricians and (paediatric) rheumatologists. One of
the aims of SHARE was to provide evidence-based
recommendations for the management of the
autoinﬂammatory diseases cryopyrin-associated periodic
syndromes (CAPS), tumour necrosis factor (TNF) receptor-
associated periodic syndrome (TRAPS) and mevalonate
kinase deﬁciency (MKD). These recommendations were
developed using the European League Against
Rheumatism standard operating procedure. An expert
committee of paediatric and adult rheumatologists was
convened. Recommendations derived from the systematic
literature review were evaluated by an online survey and
subsequently discussed at a consensus meeting using
Nominal Group Technique. Recommendations were
accepted if more than 80% agreement was reached. In
total, four overarching principles, 20 recommendations
on therapy and 14 recommendations on monitoring
were accepted with ≥80% agreement among the
experts. Topics included (but were not limited to)
validated disease activity scores, therapy and items to
assess in monitoring of a patient. By developing these
recommendations, we aim to optimise the management
of patients with CAPS, TRAPS and MKD.
INTRODUCTION
Autoinﬂammatory diseases (AID) are rare disorders
that affect multiple organ systems and lead to sig-
niﬁcant morbidity and mortality. Due to the low
patient numbers, evidence-based guidelines for
treatment are lacking and management is mostly
based on physician’s experience. As new effective
therapeutic options are now available, early diagno-
sis and treatment might prevent signiﬁcant organ
damage. Reliable recommendations can thus help
paediatricians and (paediatric) rheumatologist in
the care of patients with these rare diseases.
In 2012, a European initiative called SHARE
(Single Hub and Access point for paediatric
Rheumatology in Europe) was launched to optimise
and disseminate diagnostic and management regi-
mens in Europe for children and young adults with
rheumatic diseases.1 One of the aims of SHARE
was to provide evidence-based recommendations
for the management of paediatric rheumatic
diseases.
In this paper, we propose recommendations
for the management of three of the main mono-
genic AID:
1. Cryopyrin-associated periodic syndromes (CAPS),
caused by gain-of-function mutations in NLRP3,
is a spectrum of diseases that includes the rela-
tively mild familial cold autoinﬂammatory syn-
drome (FCAS), the intermediate Muckle-Wells
syndrome (MWS) and the severe neonatal-onset
multisystem inﬂammatory disease (NOMID), also
known as chronic infantile neurological, cutane-
ous and articular syndrome (CINCA) and their
overlaps (FCAS-MWS and MWS-CINCA).2
CAPS is characterised by fever, urticarial rash,
conjunctivitis and articular involvement (typically
triggered by cold exposure in FCAS); more
severely affected patients with CAPS may also
have hearing loss, visual loss, chronic meningitis
and amyloidosis.3 4
2. Tumour necrosis factor (TNF) receptor-
associated periodic syndrome (TRAPS) is an
autosomal dominant inherited disease.
Mutations in TNFRSF1A lead to recurrent fever
episodes lasting, on average, 10 days, accom-
panied by varying symptoms including arthral-
gia, myalgia and abdominal pain.5
3. Mevalonate kinase deﬁciency (MKD), includ-
ing hyperimmunoglobulin D syndrome and
the more severe mevalonic aciduria (MA), is
an autosomal recessive metabolic inﬂamma-
tory disease caused by mutations in MVK,
affecting the mevalonate pathway.6 Fever epi-
sodes usually last 3–7 days, with lymphaden-
opathy, abdominal symptoms, arthralgia and a
maculopapular skin rash.7 In addition to
the systemic inﬂammation, patients with MA
have a severe metabolic phenotype, including
growth retardation, ataxia and cognitive
impairment.8
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METHODS
An international panel consisting of 22 experts in paediatric or
adult rheumatology, internal medicine or nephrology was estab-
lished to develop evidence-based recommendations for the man-
agement and treatment of CAPS, TRAPS and MKD using the
European League Against Rheumatism (EULAR) standard oper-
ating procedures for developing best practice.9 10 Eleven of 22
experts were part of the SHARE consortium; 11 additional
experts were asked to join the panel based upon their clinical
and research expertise in AID.
Systematic literature search
A systematic literature search was performed in Pubmed,
Embase and Cochrane databases on 20 June 2013. All synonyms
of CAPS, TRAPS and MKD were searched in MeSH/Emtree
terms, title and abstract. Further, we searched on ‘autoinﬂamma-
tory diseases’ and synonyms, and manually checked references
of relevant original studies and reviews for missing articles. For
more details on the literature search, refer to online
supplementary ﬁgures S1, S2 and S3. Fellows (NMtH, MO, JJ)
and experts ( JBK-D, SMB, MG, JF) selected the relevant papers
for validity assessment. Complete reference lists of full-text
screened papers can be found in the online supplement.
Validity assessment
A panel of experts (two per paper) independently graded the
selected papers on methodological quality and extracted data
using predeﬁned scoring forms for diagnostic studies,11 thera-
peutic studies12 and studies describing prognosis and complica-
tions.13 Discrepancies were resolved by discussion between the
two experts, or by the opinion of a third expert in select
instances. Adapted classiﬁcation tables for diagnostic,14 thera-
peutic9 and epidemiological studies15 were used to determine
the level of evidence and the strength of each recommendation.
Recommendation development
Recommendations were derived from the available literature
and distributed to all experts in an online survey. The drafted
recommendations were revised according to comments from the
survey and proposed at a face-to-face consensus meeting, where
they were discussed by the use of Nominal Group Technique,16
supervised by an expert (BMF) in consensus building.
Recommendations were accepted when ≥80% of the experts
agreed.
RESULTS
Literature review
The literature search yielded 1698 unique papers for CAPS, 523
for TRAPS and 618 for MKD. After title/abstract and subse-
quently full-text screening, 25 CAPS papers, 22 TRAPS papers
and 28 MKD papers were assessed for validity and level of evi-
dence, of which 17/25, 17/22 and 17/28 respectively were con-
sidered valid and used for recommendation synthesis. For more
details, refer to online supplementary ﬁgures S1, S2 and S3.
Recommendations
In the following section, we describe each recommendation
with the corresponding supporting literature and discuss issues
regarding practical implementation. Tables 1–3 summarise the
recommendations, their levels of evidence, the recommendation
strength and percentage of expert agreement for each. Four add-
itional recommendations, speciﬁcally on diagnosis of TRAPS
and MKD can be found in online supplementary table S1.
Recommendations that did not meet ≥80% agreement are listed
in online supplementary table S2.
Overarching principles
AID affect multiple organ systems with potentially severe com-
plications;4 5 7 8 17–26 hence, management of these patients is
complex and warrants a multidisciplinary approach: this could
involve physiotherapists, paediatricians, rheumatologists and
other specialists when speciﬁc organs are involved, for example,
ENT specialists, ophthalmologists or nephrologists.
Furthermore, access to genetic expertise is important because
interpretation of genetic results and genetic counselling for
family members may be challenging.27 For MA, expertise in
metabolic diseases is also required.
Given the lifelong duration of AID and impact on patients’
and families’ life, care should be patient-centred and family-
centred, as is the case for most (chronic) diseases.28 Patients
with CAPS, TRAPS and MKD have an impaired quality of life
compared with healthy controls, in both physical and psycho-
social domains, and could encounter limitations in education
and daily activities.7 25 29 It is therefore important to offer psy-
chosocial support as appropriate.
Treatment goals should include control of the disease activity
and prevention of organ damage, since effective therapy might
prevent or stabilise organ damage.21 30 31 Effective treatment
can also improve participation in daily activities and quality of
life; this is thus an important additional goal of therapy.31–33
Table 1 Overarching principles for CAPS, TRAPS and MKD
Overarching principles L S Agree (%)
Management of patients with AID should ideally be guided by a multidisciplinary team in a tertiary centre
with expertise in AID, with access to genetic counselling
4 D 100
The care of patients with AID should include shared patient-centred and family-centred decision-making
with the multidisciplinary team
4 D 100
Aims of the treatment of AID include:
▸ Early and rapid control of disease activity
▸ Prevention of disease and treatment-related damage
▸ Enabling participation in daily activities
▸ Improvement of health-related quality of life
4 D 100
In patients with AID, psychosocial support is recommended as appropriate 4 D 100
L, level of evidence; 4, expert opinion; S, strength of recommendation; D, based on level 4 evidence.9 Agree, percentage of experts who agreed on the recommendation during the final
voting round of the consensus meeting.
AID, autoinflammatory diseases; CAPS, cryopyrin-associated periodic syndromes; MKD, mevalonate kinase deficiency; TRAPS, tumour necrosis factor receptor-associated periodic
syndrome.
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Diagnosis
Early diagnosis is crucial to enable treatment initiation before
damage occurs. Although diagnostic delay has decreased in the
last decades, the median time between onset of symptoms and
diagnosis is still 1–2 years.34 The diagnostic score for molecular
analysis of patients with recurrent fever35 and the recently pub-
lished clinical classiﬁcation criteria for the diagnosis of mono-
genic AID36 can facilitate the diagnostic process and decrease
this delay. We refer to these papers for more details. For CAPS,
diagnostic criteria are currently being developed.
Interpretation of genetic tests can also be challenging, espe-
cially with low-penetrance TNFRSF1A mutations or NLRP3
mutation-negative CAPS patients. Recently published guidelines
for genetic diagnosis of AID can guide physicians and geneti-
cists.27 We support the use of these guidelines in the diagnostic
process. Speciﬁc recommendations on diagnosis, for example,
the use of serum immunoglobulin D and urinary mevalonic acid
excretion in the diagnostic process of MKD, can be found in
supplementary table S1.
Therapy
Cryopyrin-associated periodic syndromes
Three interleukin (IL)-1 blocking agents are currently used for
CAPS. For a summary of the evidence and the authorisation of
the European Medicines Agency (EMA) and Food and Drug
Administration (FDA), refer to table 4 and the websites of both
organisations.37 38
Anakinra was effective in observational studies of patients
with CINCA/NOMID (aged 9 months–42 years),31 39 40 MWS
(3–75 years)40–42 and adult patients with FCAS.40 43 Starting
dose of anakinra varied between 0.5 and 2 mg/kg/day (children)
or 100 mg (adults) subcutaneously, but some patients, especially
young children, required dose escalation up to 5 or 8 mg/kg/day
to achieve sustained remission.31 42 A study on pharmacokinet-
ics of anakinra supports this ﬁnding: in order to reach the same
effective steady-state concentration, young children need higher
doses of anakinra.44
Canakinumab was effective in two randomised controlled trials
(RCTs) of patients with CAPS (MWS and CINCA/MWS-overlap,
aged 9–74 years),32 45 and in four observational studies of all
disease phenotypes and age categories.40 42 46 47 Canakinumab
was administered subcutaneously at a dose of 2 mg/kg (children)
or 150 mg (adults) once per 8 weeks, but one study mentions that
24% of 166 patients required dose escalation up to 8 mg/kg or
600 mg; this was especially the case for paediatric patients or
patients with more severe phenotypes.47
The efﬁcacy of rilonacept (2.2 mg/kg or 160 mg weekly) was
demonstrated in one RCT including adult patients with MWS
Table 2 Recommendations for the treatment of CAPS, TRAPS and MKD
L S Agree (%)
Treatment CAPS
IL-1 inhibition is indicated for the whole spectrum of CAPS, at any age 1B–2A* A–B 94.4
To prevent organ damage, long-term IL-1 inhibition should be started as early as possible in patients with active disease 2B B 100
There is no evidence for the efficacy of DMARDs or biological therapy other than IL-1 blockade in CAPS 4 D 94.4
For symptomatic adjunctive therapy, short courses of NSAIDs and corticosteroids may be used,# but they should not be used for primary
maintenance therapy##
#3
##4
#C
##D
100
In patients with CAPS, adjunctive therapy (eg, physiotherapy, orthotic devices, hearing aids) is recommended as appropriate 4 D 100
Treatment TRAPS
NSAIDs may provide symptom relief during inflammatory attacks 3 D 100
Short-term glucocorticoids, with or without NSAIDs, are effective for terminating inflammatory attacks 3 C 100
The beneficial effect of corticosteroids can decline over time so that increasing doses are required to achieve an equivalent response 3 C 100
IL-1 blockade is beneficial in the majority of patients with TRAPS. 2B B 100
Etanercept can be effective in some patients, but the effect might decline over time 2B C 93.8
With frequent attacks and/or subclinical inflammation between attacks, maintenance therapy with IL-1 blockade or etanercept is
recommended and may limit corticosteroid exposure
2B–3* C 100
If one IL-1 blocking agent at adequate dose is ineffective or intolerable, a switch to etanercept or another IL-1 blocking agent should
be considered Likewise, if etanercept is ineffective or intolerable, a switch to an IL-1 blocking agent should be considered
4 D 100
Although a beneficial effect is reported in a few cases, the use of anti-TNF monoclonal antibodies is not advised, due to the possible
detrimental effect
3 C 100
Treatment MKD
NSAIDs may provide symptom relief during inflammatory attacks 3 C 100
Short-term glucocorticoids, with or without NSAIDs, may be effective for alleviating inflammatory attacks 3 C 100
Colchicine or statins are not efficacious; therefore we do not recommend their use 3 C 100
Short-term IL-1 blockade may be effective for terminating inflammatory attacks and should be considered to limit or prevent steroid
side effects
2B C 100
With frequent attacks and/or subclinical inflammation between attacks, maintenance therapy with IL-1 blockade or etanercept is
recommended, and may limit corticosteroid exposure
2B–3* C 93.3
If one IL-1 blocking agent at adequate dose is ineffective or intolerable, a switch to another IL-1 blocking agent or another biological
agent (including TNF-α blockade or IL-6 blockade) should be considered. Likewise, if TNF-α blockade is ineffective or intolerable, a
switch to another biological agent (including an IL-1 or IL-6 blocking agent) should be considered
4 D 100
In selected cases with severe refractory disease with poor quality of life, referral to a specialist centre for consideration of allogeneic
haematopoietic stem cell transplantation is recommended.
3 D 93.3
L, level of evidence; 1B, randomised controlled study; 2A, controlled study without randomisation; 2B, quasi-experimental study; 3, descriptive study; 4, expert opinion; S, strength of
recommendation; A, based on level 1 evidence; B, based on level 2 or extrapolated from level 1; C, based on level 3 or extrapolated from level 1 or 2; D, based on level 4 or
extrapolated from level 3 or 4 evidence.9 Agree, percentage of experts who agreed on the recommendation during the final voting round of the consensus meeting.
*See table 4 for detailed information on evidence and approval of IL-1 blocking and TNF-blocking agents.
CAPS, cryopyrin-associated periodic syndromes; DMARDs, disease-modifying antirheumatic drugs; IL, interleukin; MKD, mevalonate kinase deficiency; NSAIDs, non-steroidal
anti-inflammatory drugs; TNF, tumour necrosis factor; TRAPS, tumour necrosis factor receptor-associated periodic syndrome.
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and FCAS48 and two observational studies including patients
with MWS and FCAS aged 12–80 years.40 49
In CAPS, there is no evidence for the efﬁcacy of disease-
modifying antirheumatic drugs or biological therapy other than
IL-1 blockade.50 Some patients beneﬁt from non-steroidal anti-
inﬂammatory drugs (NSAIDs) and corticosteroids, mostly as
on-demand symptom relief next to IL-1 blocking agents.39 50
Because of the lack of valid literature on efﬁcacy and prevention
of organ damage if used solely, we do not recommend the use
of NSAIDs and corticosteroids without IL-1 inhibition.
Organ damage such as hearing loss, neurological damage and
joint deformity causes considerable morbidity in patients with
CAPS and can partly be stabilised or improved with IL-1
inhibition.21 30 31 51 Therefore, it is important to start IL-1
inhibition early, before severe damage occurs. When patients
develop irreversible damage, they may need adjunctive therapy
such as physiotherapy, orthotic devices and hearing aids.
TNF receptor-associated periodic syndrome
Evidence for therapy of patients with TRAPS relies on retro-
spective cohorts or small prospective studies at best. In one
retrospective cohort, NSAIDs provided symptom relief in
approximately 75% of patients with TRAPS, but were rarely
completely effective in terminating inﬂammatory episodes.50
Efﬁcacy of corticosteroids has only been assessed in
Table 3 Recommendations for monitoring of CAPS, TRAPS and MKD
L S Agree (%)
Monitoring—overarching principles
Monitoring of disease activity and damage is important in patients with AID and should be done regularly 4 D 93.8
Monitoring frequency should depend on disease severity and activity 4 D 93.8
The Autoinflammatory Diseases Activity Index (AIDAI) is a validated tool to assess disease activity and should be used in clinical studies of
patients with TRAPS and MKD
2B B 100
Physicians should consider other potential causes (eg, infections) when patients experience inflammatory episodes that are atypical of their disease 4 D 100
Prior to therapy with biological agents, consideration should be made to give live and killed vaccines as appropriate. There are currently
insufficient safety data to recommend live vaccines during therapy with biological agents.
4 D 100
Monitoring CAPS
Monitoring in all patients with CAPS should include:
▸ General physical examination, emphasising musculoskeletal and neurological examination, and growth and development of children
▸ Blood count and inflammatory parameters, such as C-reactive protein (CRP) and serum amyloid A (SAA), if available
▸ Disease activity, using a validated tool
▸ Hearing (audiograms) and ophthalmological examination
▸ Testing for proteinuria
▸ Impact of disease on well-being, functioning and social participation
4 D 100
For monitoring the disease course of patients with more severe phenotypes, consider including the following tests:
▸ Cognitive testing
▸ Lumbar puncture (pressure, cells, protein level)
▸ Bone MRI and skeletal X-ray
▸ Brain MRI (including imaging of the inner ear)
4 D 100
Monitoring TRAPS
Monitoring in all patients with TRAPS should include:
▸ General physical examination and growth and development of children.
▸ Full blood count and inflammatory parameters, such as CRP and SAA, if available
▸ Disease activity, using a validated tool
▸ Testing for proteinuria
▸ Impact of disease on well-being, functioning and social participation
4 D 100
Interpretation of the significance of the R92Q and P46L sequence variants can be difficult. These occur at a high frequency in healthy controls,
and their pathogenic significance remains contentious. Some individuals develop a clinical phenotype of TRAPS, although sometimes with shorter
and/or more frequent fever episodes.
2B B 100
Generally, patients carrying R92Q or P46L have milder disease and a better prognosis (improvement over time; and low risk of AA amyloidosis)
compared with structural TNFRSF1A mutations.
1B B 89.5
Patients with chronic, persistent disease activity have a higher risk of developing AA amyloidosis. 2B B 100
Monitoring MKD
Monitoring in all patients with MKD should include:
▸ General physical examination; and growth and development of children
▸ Full blood count and inflammatory parameters, such as CRP and SAA, if available
▸ Disease activity, using a validated tool
▸ Analysis for proteinuria and haematuria
▸ Impact of disease on well-being, functioning and social participation
▸ Ophthalmological examination
4 D 87.5
For monitoring the disease course of patients with more severe phenotypes, consider including the following examinations:
▸ Cognitive testing
▸ Muscle and liver enzymes
▸ Specific neurological examination
4 D 100
Besides infections, physicians should also be alert to the possibility of macrophage activation syndrome in patients with MKD. 3 C 100
L, level of evidence; 1B, prospective cohort study with good follow-up; 2B, retrospective cohort study, or prospective with poor follow-up; 3, non-consecutive or limited cohort study; 4,
case series or expert opinion. S, strength of recommendation; B, based on level 2 or extrapolated from level 1; C, based on level 3 or extrapolated from level 1 or 2; D, based on level 4
or extrapolated from level 3 or 4 evidence.15 Agree, percentage of experts who agreed on the recommendation during the final voting round of the consensus meeting.
AID, autoinflammatory diseases; CAPS, cryopyrin-associated periodic syndromes; MKD, mevalonate kinase deficiency; TRAPS, tumour necrosis factor receptor-associated periodic syndrome.
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retrospective studies, in which most patients reported a beneﬁ-
cial effect.23 50 52–54 Unfortunately, this initial favourable
response often declines with time.53
A summary of the evidence and authorisation details for IL-1
blocking and TNF-blocking agents is provided in table 4.
Etanercept efﬁcacy was assessed in two small prospective
studies; these demonstrated signiﬁcant improvement in symp-
toms and inﬂammatory parameters in most patients but also
highlighted declining efﬁcacy over time. This latter ﬁnding was
the reason for discontinuing etanercept in 11/13 patients in one
study.55–57 Loss of etanercept efﬁcacy was also reported in
larger retrospective studies describing transient responses, and a
complete remission rate of less than one-third of patients.50 58
Anakinra was effective as on-demand as well as maintenance
therapy in a small prospective study.59 Retrospective studies
conﬁrm this ﬁnding; a complete response was reported in
two-thirds of the patients.50 58 However, anakinra-failure was
also observed.50 60
Because long-term disease activity can cause AA amyloidosis5
and long-term use of corticosteroids can induce signiﬁcant side-
effects,61–63 we recommend maintenance therapy with IL-1
blockade or etanercept in patients with frequent attacks and/or
ongoing (subclinical) inﬂammation. In retrospective studies,
IL-1 blockade seems to be superior to etanercept.50 However, as
prospective randomised trials comparing efﬁcacy between these
drugs are lacking, insufﬁcient evidence is available to clearly rec-
ommend one speciﬁc agent as ﬁrst-line.
Evidence in TRAPS for switching from one biological agent
to another is restricted to one study that showed efﬁcacy of
anakinra after patients experienced loss of efﬁcacy to etaner-
cept.55 Studies in other diseases also suggest that switching
could be beneﬁcial and should be considered when the initial
treatment choice is ineffective or intolerable.42 64 For IL-1
blockade, dose adjustments might be necessary to achieve
complete response, as has been shown in patients with
CAPS.31 42 44 47
The use of adalimumab and inﬂiximab induces variable results
in case reports, including failure and even worsening of TRAPS
symptoms; these drugs are thus not recommended.50 56 57
Mevalonate kinase deﬁciency
Treatment efﬁcacy in MKD is mostly described in retrospective
cohorts. Most patients beneﬁted from the use of NSAIDs,
mainly given during inﬂammatory attacks.7 8 50 However,
NSAIDs are not effective for terminating inﬂammatory attacks.
Similarly, the efﬁcacy of glucocorticoids has only been assessed
retrospectively, and most patients derive some therapeutic
beneﬁt.7 8 50 Colchicine and statins are ineffective; moreover,
statins induced a severe attack in a patient with MA.7 8 26 50
A small prospective study showed that anakinra on demand sig-
niﬁcantly reduced all features of the fever episode compared with
attacks not treated with anakinra.65 When patients have frequent
attacks and/or subclinical inﬂammation between attacks, mainten-
ance therapy with IL-1 blockade or etanercept is recommended.
Continuous IL-1 blockade with anakinra or canakinumab, or
TNF-blockade with etanercept or adalimumab, was beneﬁcial in
approximately two-thirds of reported patients.7 26 50 66 Because
head-to-head comparisons are lacking, it is not possible to recom-
mend any one of these agents as ﬁrst-line biological therapy.
Table 4 summarises the evidence relating to IL-1 and TNF-blocking
agents in MKD. Although there is currently no evidence to support
switching biological agents in MKD when initial treatment fails,
based on the success of this approach in other diseases,42 64 this
should be considered. Again, for IL-1 blockade, dose adjustments
might be tried ﬁrst, as the initial dose might be insufﬁcient.
In selected cases with severe refractory disease and poor
quality of life, allogeneic haematopoietic stem cell transplant-
ation (HSCT) could be a valuable option. Four cases of success-
ful allogeneic HSCT have been reported: all experienced a
remission of systemic inﬂammation and an improvement of
neurological symptoms.67–69 Nonetheless, because of the inher-
ent risks associated with HSCT, this should only be considered
in severely affected patients resistant to (or intolerant of) all the
other aforementioned therapeutic agents.
Monitoring
General
Since disease-related and treatment-related morbidity is common,
and dose adjustment of IL-1 blocking agents to achieve complete
Table 4 Summary of evidence and regulatory authorisations for IL-1 blockade and TNF-blockade
L EMA approval FDA approval
CAPS
Canakinumab 1B Approved for patients with CINCA/NOMID, MWS and ‘severe
FCAS’* ≥2 years and ≥7.5 kg body weight
Approved for patients with FCAS and MWS ≥4 years
Rilonacept 1B – Approved for patients with FCAS and MWS ≥12 years
Anakinra 2A Approved for all patients with CAPS ≥8 months and ≥10 kg body weight Approved for patients with CINCA/NOMID (all ages)
TRAPS
Canakinumab 3 Orphan designation –
Anakinra 2B – –
Etanercept 2B – –
MKD
Canakinumab 3 – –
Anakinra 2B – –
Etanercept 3 – –
Adalimumab 3 – –
L, level of evidence as assessed in a systematic review up to June 2013. 1B, randomised controlled study; 2A, controlled study without randomisation; 2B, quasi-experimental study; 3,
descriptive study.9 Approval as published on websites of EMA (European Medicines Agency) and FDA (US Food and Drug Administration) up to June 2015.37 38
*Severe FCAS is defined by EMA as FCAS presenting with signs and symptoms beyond cold-induced urticarial skin rash.
CAPS, cryopyrin-associated periodic syndromes; CINCA, chronic, infantile, neurological, cutaneous and articular syndrome; FCAS, familial cold autoinflammatory syndrome; IL,
interleukin; MKD, mevalonate kinase deficiency; MWS, Muckle-Wells syndrome; NOMID, neonatal-onset multisystem inflammatory disease; TNF, tumour necrosis factor; TRAPS, tumour
necrosis factor receptor-associated periodic syndrome.
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remission may be required, regular monitoring is crucial.39 47
Disease severity varies widely among patients, and thus we recom-
mend that the speciﬁc monitoring frequency should be tailored to
suit individual patient requirements.
The use of a validated disease activity score is crucial for stan-
dardised monitoring of patients with AID. The Autoinﬂammatory
Diseases Activity Index (AIDAI) is the only validated disease activ-
ity index for TRAPS and MKD, and one of the validated scores
for CAPS.70 71 Another validated disease activity score for patients
with CAPS is the MWS Disease Activity Score (MWS-DAS).72 To
increase standardised outcome measurements and thus improve
comparisons between studies, we recommend that a validated
score should be used in clinical studies of patients with AID: the
AIDAI for TRAPS and MKD, and either the AIDAI or MWS-DAS
for CAPS.
During monitoring, patients may experience inﬂammatory
episodes that are atypical of their disease; it is important to be
aware of other causes of these atypical episodes. Infections are
common, especially in children, and might be more common or
more dangerous in patients with AID due to their disease and/or
immunosuppressive medication.26 31 39 41–43 45 47 49 73 When
initiating therapy with biological agents, consideration should
be made to give live-attenuated and non-live vaccines as appro-
priate. According to EULAR recommendations for vaccination
in patients with rheumatic diseases, physicians should withhold
live-attenuated vaccines when a patient is treated with biological
agents.74 75 Some studies suggest that live-attenuated booster
vaccination against measles-mumps-rubella and yellow fever can
be safely used in patients using TNF-blocking agents.76–78
Evidence on safety of vaccinations during IL-1 blocking agents
is limited to one randomised study of healthy subjects79 and a
note that 25 patients with CAPS on canakinumab received vacci-
nations without abnormal immune responses or pathogen-
related infections.47 However, data on live-attenuated vaccines
are still scarce; hence we concluded that there are currently
insufﬁcient safety data to recommend live vaccines during
therapy with biological agents, especially during IL-1 blockade.
Cryopyrin-associated periodic syndromes
Experts created a list of items that should be included in the
monitoring of all patients with CAPS (table 3), based on all rele-
vant symptoms and complications described in patients with
CAPS as well as the impact of disease on daily
life.17 18 20 21 30 32 72 80–83 For the more severe CAPS pheno-
types, additional tests such as imaging of bone and brain, includ-
ing inner ear should be considered, as well as cognitive testing
and lumbar puncture to assess chronic meningitis. Because bone
overgrowth mainly involves the lower limbs, we recommend
performing imaging (including skeletal X-ray and MRI) of the
femurs, patellae and tibiae.
TNF receptor-associated periodic syndrome
Most TRAPS symptoms can be assessed by history taking and
physical examination.5 22–25 Amyloidosis is described in about
10% of the patients with TRAPS and occurs more often in
patients with long disease duration.5 22 23 84 Hence, inﬂamma-
tory parameters and proteinuria should be checked regu-
larly.5 22 23 A list of particularly relevant items to check when
monitoring a patient with TRAPS can be found in table 3.
Interpretation of the low-penetrance variants R92Q and P46L
can be difﬁcult, as 1%–2% of asymptomatic controls also
harbour these variants.22 84 Patients with R92Q or P46L var-
iants who experience symptoms compatible with TRAPS have a
similar phenotype as patients with other TNFRSF1A mutations,
although sometimes with shorter and/or more frequent fever
episodes.5 23 25 These patients are also more likely to have a
milder disease course (resolution or decrease in fever episodes)
and a decreased risk of developing AA amyloidosis compared
with patients with structural TNFRSF1A mutations.5 22 23 25
Mevalonate kinase deﬁciency
Most of the mild MKD symptoms can be assessed by history
taking and physical examination and routine laboratory mea-
sures such as full blood count, C-reactive protein (CRP) and
serum amyloid A (SAA) to assess systemic inﬂammation.7 26
Urine analysis should be performed for renal complications such
as AA amyloidosis, glomerulonephritis and renal angiomyoli-
poma7 26 as well as ophthalmological examination for retinitis
pigmentosa and cataracts.26 85
Patients with more severe MKD phenotypes have neurological
complications such as ataxia, hypotonia and psychomotor
retardation; thus cognitive testing and full neurological examin-
ation should be considered.8 26 Since hepatitis and myopathy
are also reported in these patients, testing muscle and liver
enzymes may be relevant. A list of items particularly relevant
for monitoring MKD is provided in table 3.
In addition to an increased infection risk, physicians should
also be aware of a higher risk of macrophage activation syn-
drome (MAS) in patients with MKD, especially in the assess-
ment of atypical fever episodes. MAS is a life-threatening
complication of some rheumatic diseases (eg, systemic juvenile
idiopathic arthritis), characterised by high fever, pancytopenia
and liver damage.86 In one cohort of patients with MKD, the
frequency of MAS was surprisingly high (6/50, 12%).26
DISCUSSION
The SHARE taskforce formulated a total of 42 recommenda-
tions for the management of patients with the autoinﬂammatory
diseases CAPS, TRAPS and MKD, based on a systematic litera-
ture review and consensus procedure.
Biological therapies have dramatically improved the outcome
of patients with AID; this is especially true for patients with
CAPS on IL-1 blockade. However, evidence supporting the use
of biologicals is still very limited in TRAPS and MKD.
Prospective studies and head-to-head comparisons are needed to
draw solid conclusions on the efﬁcacy of biologicals and to
enable EMA/FDA approval. At the time of writing, prospective
clinical trials are ongoing: two Phase 2 studies on canakinumab
for MKD (NCT01303380) and TRAPS (NCT01242813) and a
Phase 3 study on canakinumab for hereditary periodic fevers
(NCT02059291).87 Regarding the use of IL-1 blockade in very
young children with CAPS, the current regulatory approvals by
FDA and EMA are provided in table 4. It is recognised,
however, that some young patients with severe CAPS may
require treatment earlier in life than currently recommended by
the authorities. Studies on the safety of canakinumab in the very
young are soon-to-be published.
Close monitoring of patients’ symptoms, damage and well-
being is an important requirement for ‘treat to target’ strategies.
Structured long-term follow-up studies of patients with AID are
warranted to clarify complication risks. Given the rarity of these
diseases, international collaboration is crucial to recruit sufﬁ-
cient patient numbers. Validated scores for disease activity and
damage are essential in order to perform a structured assess-
ment of outcome, especially to determine long-term therapeutic
efﬁcacy and therapy-associated morbidity. Disease activity scores
have now been developed, however, disease damage scores are
still lacking.
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A signiﬁcant limitation of these recommendations is the lack
of high-quality evidence. Other than the use of IL-1 blockade in
CAPS, most topics are not thoroughly studied. Thus, most of
our recommendations have a strength C or D and depend
mainly on expert opinion. Therefore, further research on com-
plications, monitoring and the use of biological agents in
TRAPS and MKD is necessary to enable better evidence-based
recommendations. To conclude, based on the best available evi-
dence and expert opinion, this SHARE initiative provides
recommendations on diagnosis, treatment and monitoring of
CAPS, TRAPS and MKD, aiming to optimise the management
of these rare patients.
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